Literature DB >> 22173491

Preparation of anti-HER2 monoclonal antibody-paclitaxel immunoconjugate and its biological evaluation.

Dong Liu1, Yanjiao Xu2, Zichao Rao2, Zhaocong Chen3.   

Abstract

Anti-HER2 monoclonal antibody (Sc7301)-paclitaxel (TAX) immunoconjugate was prepared and its specific binding to tumor cells was investigated in this study. Sc7301 was conjugated to TAX by the active ester method and then the TAX-Sc7301 immunoconjugate was obtained. After purification and labeling by Cyano-fluorescein isothiocyanate (FITC), the specific binding of TAX-Sc7301 to HER2-positive tumor cells (SKOV3) and HER2-negative tumor cells (HepG2) was evaluated respectively. TAX-Sc7301 (20 nmol/L) showed distinct specific binding to SKOV3 cells rather than HepG2 cells. And the uptake of the immunoconjugate by SKOV3 cells was increased with the TAX-Sc7301 concentration (3-48 nmol/L) and the incubation time (P<0.05). It was concluded that the TAX-Sc7301 immunoconjugate is potentially applicable as a targeted agent against HER2-positive tumor cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22173491     DOI: 10.1007/s11596-011-0669-8

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  19 in total

1.  Paclitaxel-induced neutrophilic adverse reaction and acral erythema.

Authors:  Antonio Cruz; Tecla Temu; Gladys Hines-Telang; George Kroumpouzos
Journal:  Acta Derm Venereol       Date:  2011-01       Impact factor: 4.437

Review 2.  [Targeted cytotoxic drugs emerging for cancer therapy].

Authors:  Teemu T Junttila; Minna Tanner; Jorma Isola
Journal:  Duodecim       Date:  2011

Review 3.  An overview of monoclonal antibody therapy of cancer.

Authors:  L M Weiner
Journal:  Semin Oncol       Date:  1999-08       Impact factor: 4.929

Review 4.  Antibody-drug conjugates as targeted cancer therapeutics.

Authors:  Yu Sun; Fei Yu; Bai-Wang Sun
Journal:  Yao Xue Xue Bao       Date:  2009-09

Review 5.  Targeting of radio-isotopes for cancer therapy.

Authors:  Diane E Milenic; Martin W Brechbiel
Journal:  Cancer Biol Ther       Date:  2004-04-03       Impact factor: 4.742

6.  Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.

Authors:  Yu Cao; James D Marks; John W Marks; Lawrence H Cheung; Sehoon Kim; Michael G Rosenblum
Journal:  Cancer Res       Date:  2009-11-24       Impact factor: 12.701

7.  Synthesis and evaluation of [14C]-labelled and fluorescent-tagged paclitaxel derivatives as new biological probes.

Authors:  C S Rao; J J Chu; R S Liu; Y K Lai
Journal:  Bioorg Med Chem       Date:  1998-11       Impact factor: 3.641

8.  HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group.

Authors:  S Camilleri-Broët; A C Hardy-Bessard; A Le Tourneau; D Paraiso; O Levrel; B Leduc; S Bain; H Orfeuvre; J Audouin; E Pujade-Lauraine
Journal:  Ann Oncol       Date:  2004-01       Impact factor: 32.976

9.  Fluorescent biological label for recognizing human ovarian tumor cells based on fluorescent nanoparticles.

Authors:  Shasheng Huang; Ruina Li; Yongxia Qu; Jian Shen; Jia Liu
Journal:  J Fluoresc       Date:  2009-07-04       Impact factor: 2.217

10.  Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.

Authors:  Huaiwen Chen; Jie Gao; Ying Lu; Geng Kou; He Zhang; Li Fan; Zhiguo Sun; Yajun Guo; Yanqiang Zhong
Journal:  J Control Release       Date:  2008-03-19       Impact factor: 11.467

View more
  1 in total

1.  A Washing-Free and Easy-to-Operate Fluorescent Biosensor for Highly Efficient Detection of Breast Cancer-Derived Exosomes.

Authors:  Wenqin Chen; Yan Zhang; Kaili Di; Chang Liu; Yanyan Xia; Shijia Ding; Han Shen; Zhiyang Li
Journal:  Front Bioeng Biotechnol       Date:  2022-06-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.